Nano Carrier IR report 2017

9/12

ew Technology ▶NJoint research begins with Professor You Han Bae and others at Utah University A joint research agreement was concluded in April 2017 for oral delivery of biopharmaceuticals. The realization of oral delivery will further increase convenience, and we expect strong demand.9We continue to generate new technologies by combining micellar nanoparticles, our core technology, with the advanced technology and expertise of other companies.• Small amount of drug conjugations• Only selects highly active compounds• Concern over side effects due to high activity• Large number of expensive antibodies requiredAn advanced delivery system designed to protect nucleic acids that are quickly metabolized when administered into the body so that it can reliably deliver drugs into the cells while retaining their activity.We are conducting optimization experiments together with many companies.In March 2017, we concluded an investment and joint research agreement with TPG Biologics, Inc. (Taiwan). We are investigating sensors and active proteins suitable for our ADCM technology and broadening the possibilities for market expansion.By adding micelle (M) to existing ADC technology, we reduced significantly the problems of ADC● Delivering the drug safely and in higher volumes● Can greatly increase the choices for targeting 　　sensors and drugsNanoCarrier continues its approaches to new technologies.Revolutionary nucleic acid drugs through joint research with Chugai PharmaceuticalSignicant improvement of ADC technologyActive delivery technology that is attracting global attentionActive NanoFect®ADCMConventional ADCAntibody/Drug-Conjugated MicelleDrugs Cancer cell-specific sensor(e.g. antibodies)Candidate of siRNA drug(nucleic acid drug)Cancer cell-specific sensorNanoFect®Nucleic acid delivery system++From the research results until now, we determined that additional tests will be necessary, and in March 2017 we extended the joint research agreement with Chugai Pharmaceutical.siRNASensor (antibody)Oral ingestion of drugs reduces the burden on patients compared to injection.ActiveNanoFect®Next-generation delivery systemFirst-in-classpharmaceutical productChugai Pharmaceutical’sexpertise NanoCarrier’stechnology